Skip to main content
Log in

Rosiglitazone CV risk relative to metformin, sulfonylurea

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCE

  1. McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM.Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiology and Drug Safety 16: 711-725, No. 7, Jul 2007

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosiglitazone CV risk relative to metformin, sulfonylurea. React. Wkly. 1161, 5 (2007). https://doi.org/10.2165/00128415-200711610-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200711610-00010

Keywords

Navigation